{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T15:18:52Z","timestamp":1784647132625,"version":"3.55.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb Co","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Heart Failure"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.jchf.2023.07.030","type":"journal-article","created":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T14:30:06Z","timestamp":1697639406000},"page":"567-579","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Mavacamten for Obstructive Hypertrophic Cardiomyopathy With or Without Hypertension"],"prefix":"10.1016","volume":"12","author":[{"given":"Andrew","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Spertus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel M.","family":"Wojdyla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodore P.","family":"Abraham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ester Kim","family":"Nilles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjali Tiku","family":"Owens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Saberi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5417-1054","authenticated-orcid":false,"given":"Sharon","family":"Cresci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Sehnert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neal K.","family":"Lakdawala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jchf.2023.07.030_bib1","doi-asserted-by":"crossref","first-page":"e159","DOI":"10.1016\/j.jacc.2020.08.045","article-title":"2020 AHA\/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"76","author":"Ommen","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2023.07.030_bib2","first-page":"353","article-title":"Clinical spectrum and management of heart failure in hypertrophic cardiomyopathy","volume":"6","author":"Maron","year":"2018","journal-title":"J\u00a0Am Coll Cardiol HF"},{"issue":"19","key":"10.1016\/j.jchf.2023.07.030_bib3","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1016\/j.jacc.2017.11.005","volume":"71","author":"Whelton","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2023.07.030_bib4","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.117.004124","article-title":"Efficacy of ranolazine in patients with symptomatic hypertrophic cardiomyopathy: the RESTYLE-HCM randomized, double-blind, placebo-controlled study","volume":"11","author":"Olivotto","year":"2018","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jchf.2023.07.030_bib5","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.amjcard.2022.03.023","article-title":"Characteristics of patients with obstructive hypertrophic cardiomyopathy in real-world community-based cardiovascular practices","volume":"174","author":"Butzner","year":"2022","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jchf.2023.07.030_bib6","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1016\/j.jacc.2019.08.1057","article-title":"Distinct subgroups in hypertrophic cardiomyopathy in the NHLBI HCM Registry","volume":"74","author":"Neubauer","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2023.07.030_bib7","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1016\/j.jacc.2021.07.065","article-title":"Randomized trial of metoprolol in patients with obstructive hypertrophic cardiomyopathy","volume":"78","author":"Dybro","year":"2021","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2023.07.030_bib8","doi-asserted-by":"crossref","first-page":"52","DOI":"10.2174\/1573403X1201160126125403","article-title":"Drug therapy for hypertrophic cardiomyopathy: physiology and practice","volume":"12","author":"Sherrid","year":"2016","journal-title":"Curr Cardiol Rev"},{"key":"10.1016\/j.jchf.2023.07.030_bib9","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1002\/ejhf.541","article-title":"Pharmacological treatment of hypertrophic cardiomyopathy: current practice and novel perspectives","volume":"18","author":"Ammirati","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2023.07.030_bib10","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1080\/00498254.2018.1495856","article-title":"In\u00a0vitro and in\u00a0vivo pharmacokinetic characterization of mavacamten, a first-in-class small molecule allosteric modulator of beta cardiac myosin","volume":"49","author":"Grillo","year":"2019","journal-title":"Xenobiotica"},{"key":"10.1016\/j.jchf.2023.07.030_bib11","doi-asserted-by":"crossref","first-page":"16571","DOI":"10.1074\/jbc.M117.776815","article-title":"A\u00a0small-molecule modulator of cardiac myosin acts on multiple stages of the myosin chemomechanical cycle","volume":"292","author":"Kawas","year":"2017","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jchf.2023.07.030_bib12","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jacc.2022.04.048","article-title":"Myosin inhibition in patients with obstructive hypertrophic cardiomyopathy referred for septal reduction therapy","volume":"80","author":"Desai","year":"2022","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2023.07.030_bib13","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","article-title":"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"396","author":"Olivotto","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jchf.2023.07.030_bib14","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1016\/S0140-6736(21)00763-7","article-title":"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): health status analysis of a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"397","author":"Spertus","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jchf.2023.07.030_bib15","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.120.006853","article-title":"Study design and rationale of EXPLORER-HCM: evaluation of mavacamten in adults with symptomatic obstructive hypertrophic cardiomyopathy","volume":"13","author":"Ho","year":"2020","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jchf.2023.07.030_bib16","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/S0735-1097(00)00531-3","article-title":"Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure","volume":"35","author":"Green","year":"2000","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2023.07.030_bib17","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1016\/j.amjmed.2022.05.006","article-title":"Changing demographics in hypertrophic cardiomyopathy and\u00a0implications for management: clinical research","volume":"135","author":"Maron","year":"2022","journal-title":"Am J Med"},{"issue":"12","key":"10.1016\/j.jchf.2023.07.030_bib18","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.115.003285","article-title":"T1 mapping in discrimination of hypertrophic phenotypes: hypertensive heart disease and hypertrophic cardiomyopathy: findings from the international T1 multicenter cardiovascular magnetic resonance study","volume":"8","author":"Hinojar","year":"2015","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.jchf.2023.07.030_bib19","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1093\/oxfordjournals.eurheartj.a059594","article-title":"Morphological quantification and differentiation of left ventricular hypertrophy in hypertrophic cardiomyopathy and hypertensive heart disease. A two dimensional echocardiographic study","volume":"11","author":"Keller","year":"1990","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jchf.2023.07.030_bib20","series-title":"Hypertension prevalence among adults 18 and over: United States, 2017-2018. NCHS Data Brief, no 364","author":"Ostchega","year":"2020"},{"key":"10.1016\/j.jchf.2023.07.030_bib21","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1136\/hrt.44.4.395","article-title":"Echocardiographic differentiation of hypertensive heart disease and hypertrophic cardiomyopathy","volume":"44","author":"Doi","year":"1980","journal-title":"Br Heart J"},{"key":"10.1016\/j.jchf.2023.07.030_bib22","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S2213-8587(14)70241-4","article-title":"Efficacy and safety of the angiotensin II receptor blocker losartan for hypertrophic cardiomyopathy: the INHERIT randomised, double-blind, placebo-controlled trial","volume":"3","author":"Axelsson","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jchf.2023.07.030_bib23","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1016\/j.jacc.2021.09.1381","article-title":"Effect of mavacamten on echocardiographic features in symptomatic patients with obstructive hypertrophic cardiomyopathy","volume":"78","author":"Hegde","year":"2021","journal-title":"J\u00a0Am Coll Cardiol"}],"container-title":["JACC: Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221317792300522X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221317792300522X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T05:04:55Z","timestamp":1761973495000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221317792300522X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S221317792300522X"],"URL":"https:\/\/doi.org\/10.1016\/j.jchf.2023.07.030","relation":{},"ISSN":["2213-1779"],"issn-type":[{"value":"2213-1779","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mavacamten for Obstructive Hypertrophic Cardiomyopathy With or Without Hypertension","name":"articletitle","label":"Article Title"},{"value":"JACC: Heart Failure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchf.2023.07.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}